期刊
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.632717
关键词
MSC; clinical translation challenge; metrology and characterization; commercialization; biotherapeutic development
资金
- Midwest Institute for Comparative Stem Cell Biotechnology
- Terry Johnson Center for Basic Cancer Research
The promise of MSCs as a therapeutic modality has not yet translated to consistent, successful clinical trial results in humans, despite preclinical data demonstrating their potential. MSC shareholders aim to improve the quality of life for patients with suboptimal or ineffective standard care. Although there are no FDA-approved MSC therapies in the US market, several MSC products have received regulatory approval in other countries.
Following their discovery over 50 years ago, mesenchymal stromal cells (MSCs) have become one of the most studied cellular therapeutic products by both academia and industry due to their regenerative potential and immunomodulatory properties. The promise of MSCs as a therapeutic modality has been demonstrated by preclinical data yet has not translated to consistent, successful clinical trial results in humans. Despite the disparities across the field, MSC shareholders are unified under one common goal-to use MSCs as a therapeutic modality to improve the quality of life for those suffering from a malady in which the standard of care is suboptimal or no longer effective. Currently, there is no Food and Drug Administration (FDA)-approved MSC therapy on the market in the United States although several MSC products have been granted regulatory approval in other countries. In this review, we intend to identify hurdles that are impeding therapeutic progress and discuss strategies that may aid in accomplishing this universal goal of widespread therapeutic use.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据